RxDoctor Payments Data

Holly Cuevas, NP

Family · Gulfport, MSNPI 1689234635

Payments from drug & device makers

$2,899in general payments, 2019–2025

Across 134 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$572
  • AbbVie$549
  • Lilly USA, LLC$476
  • Novo Nordisk$386
  • Johnson & Johnson$296
  • Amgen$129
  • plus $491 from 11 others

What the payments were for

  • Food & beverage$2,899100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,899 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$22,532
Medicare patients
108
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$31,001
JardianceEmpagliflozin14$18,664
FarxigaDapagliflozin Propanediol15$13,452
EliquisApixaban19$11,666
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,517
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,489
Rosuvastatin Calcium137$1,211
Atorvastatin Calcium131$654
Albuterol Sulfate HfaAlbuterol Sulfate26$587
Fenofibrate14$574
Ezetimibe44$560
Gabapentin30$544
Escitalopram Oxalate49$473
Telmisartan20$466
Fluticasone Propionate40$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$386$31,00123 claims
AstraZenecaFarxiga, Breztri Aerosphere$572$23,97030 claims
Boehringer IngelheimJardiance$22$18,66414 claims
PfizerEliquis$128$11,66619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →